Skip to content

Author

N. Kootstra

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Anti-capsid nanobodies function as HIV-1 capsid inhibitors by intracellular capsid degradation.

Antiretroviral therapy (ART) strategies against HIV-1 have been successful in suppressing HIV-1 replication and preventing disease progression. However, drug-resistance development, side-effects and life-long adherence of current drugs have driven the development of novel inhibitors against HIV-1. Inhibition of capsid...

F. M. Stel, Charlotte E J Verkuijlen, E. Zijlstra-Willems et al. · 1 citation
Open access Jul 2026

Siglec-1-targeted nanobodies restrict HIV-1 transmission and infection of dendritic cells

Newly developed single-domain antibodies against Siglec-1 are used against Siglec-1 as a candidate inhibitor to limit HIV-1 transmission and support the development of host-directed nanobody-based strategies to reduce HIV-1 spread.

S. Man, A. Affandi, H. Brink et al. · 0 citations
Open access Aug 2026

Capsid-Targeting Biologic Achieves Broad HIV-1 Neutralization with a High Barrier to Resistance

The results demonstrate the broad neutralization potential of anti-capsid biologics with a high barrier to resistance, making capsid-targeting inhibitors important for novel antiretroviral drug strategies worldwide.

F. M. Stel, E. Zijlstra-Willems, A. van Nuenen et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.